Related Experiment Video

Updated: Jan 25, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy

Wouter T Zandee1, Richard A Feelders1, Daan A Smit Duijzentkunst2

  • 1Department of Internal Medicine, Sector Endocrinology.

European Journal of Endocrinology
|May 9, 2019
PubMed
Abstract

Insights

Radioligand therapy with 177Lutetium DOTATATE offers a safe and effective treatment for rare inoperable or malignant paragangliomas and pheochromocytomas, showing significant tumor control.

Area of Science:

  • Endocrinology
  • Nuclear Medicine
  • Oncology

Background:

  • Paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare neuroendocrine tumors with limited systemic treatment options.
  • Inoperable or metastatic disease presents a significant clinical challenge.

Purpose of the Study:

  • To evaluate the safety and efficacy of (177LutetiumDOTA0-Tyr3)octreotate (177Lu-DOTATATE) in patients with inoperable or malignant PGLs and PCCs.
  • To assess tumor response and progression-free survival following peptide receptor radionuclide therapy (PRRT).

Main Methods:

  • Retrospective analysis of 30 patients with histologically confirmed inoperable or malignant PGLs and PCCs treated with 177Lu-DOTATATE.
  • Patients received up to four cycles of 7.4 GBq 177Lu-DOTATATE.
  • Tumor response assessed using RECIST 1.1 criteria.

Main Results:

  • Overall tumor control (partial response or stable disease) was achieved in 30 of 30 patients (100%).
  • Grade 3/4 hematotoxicity occurred in 20% of patients; two experienced reversible cardiac events.
  • Median progression-free survival varied by tumor type: 91 months (parasympathetic PGLs), 13 months (sympathetic PGLs), and 10 months (metastatic PCCs).

Conclusions:

  • Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is a safe and effective treatment modality for inoperable or malignant PGLs and PCCs.
  • The treatment demonstrates significant potential for tumor control and prolonged progression-free survival in this patient population.

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.8K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.5K

Related Concept Videos

Peptide Bonds02:43

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
451
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.4K